Cargando…
Maculopapular Exanthema After the Second Dose of Evolocumab
Evolocumab is a relatively new monoclonal antibody designed to decrease low-density lipoproteins via the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). It is used alone or in combination with other lipid-lowering agents. Evolocumab was associated with adverse events of skin ras...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229243/ https://www.ncbi.nlm.nih.gov/pubmed/34188988 http://dx.doi.org/10.7759/cureus.15249 |
_version_ | 1783712931567894528 |
---|---|
author | Ghernautan, Victoria Amini, Masoud Sachmechi, Issac |
author_facet | Ghernautan, Victoria Amini, Masoud Sachmechi, Issac |
author_sort | Ghernautan, Victoria |
collection | PubMed |
description | Evolocumab is a relatively new monoclonal antibody designed to decrease low-density lipoproteins via the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). It is used alone or in combination with other lipid-lowering agents. Evolocumab was associated with adverse events of skin rashes in clinical trials. We describe a rare case of maculopapular exanthema in a female patient with hyperlipidemia, which was treated with evolocumab. The patient was a 60-year-old female with hyperlipidemia who experienced a maculopapular rash after she was administered the second dose of evolocumab subcutaneously. The rash occurred on her torso and upper extremities and was associated with pruritus and mild wheezing. The hypersensitivity reaction was treated with antihistamines and with the discontinuation of evolocumab. The skin eruption cleared within 10 days. In conclusion, medical professionals should be aware of evolocumab skin hypersensitivity reactions, which could demand the cessation of the evolocumab treatment. |
format | Online Article Text |
id | pubmed-8229243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-82292432021-06-28 Maculopapular Exanthema After the Second Dose of Evolocumab Ghernautan, Victoria Amini, Masoud Sachmechi, Issac Cureus Endocrinology/Diabetes/Metabolism Evolocumab is a relatively new monoclonal antibody designed to decrease low-density lipoproteins via the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). It is used alone or in combination with other lipid-lowering agents. Evolocumab was associated with adverse events of skin rashes in clinical trials. We describe a rare case of maculopapular exanthema in a female patient with hyperlipidemia, which was treated with evolocumab. The patient was a 60-year-old female with hyperlipidemia who experienced a maculopapular rash after she was administered the second dose of evolocumab subcutaneously. The rash occurred on her torso and upper extremities and was associated with pruritus and mild wheezing. The hypersensitivity reaction was treated with antihistamines and with the discontinuation of evolocumab. The skin eruption cleared within 10 days. In conclusion, medical professionals should be aware of evolocumab skin hypersensitivity reactions, which could demand the cessation of the evolocumab treatment. Cureus 2021-05-26 /pmc/articles/PMC8229243/ /pubmed/34188988 http://dx.doi.org/10.7759/cureus.15249 Text en Copyright © 2021, Ghernautan et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Endocrinology/Diabetes/Metabolism Ghernautan, Victoria Amini, Masoud Sachmechi, Issac Maculopapular Exanthema After the Second Dose of Evolocumab |
title | Maculopapular Exanthema After the Second Dose of Evolocumab |
title_full | Maculopapular Exanthema After the Second Dose of Evolocumab |
title_fullStr | Maculopapular Exanthema After the Second Dose of Evolocumab |
title_full_unstemmed | Maculopapular Exanthema After the Second Dose of Evolocumab |
title_short | Maculopapular Exanthema After the Second Dose of Evolocumab |
title_sort | maculopapular exanthema after the second dose of evolocumab |
topic | Endocrinology/Diabetes/Metabolism |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229243/ https://www.ncbi.nlm.nih.gov/pubmed/34188988 http://dx.doi.org/10.7759/cureus.15249 |
work_keys_str_mv | AT ghernautanvictoria maculopapularexanthemaaftertheseconddoseofevolocumab AT aminimasoud maculopapularexanthemaaftertheseconddoseofevolocumab AT sachmechiissac maculopapularexanthemaaftertheseconddoseofevolocumab |